Anti-Inflammatory Biologics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Anti-Inflammatory Biologics Market
The anti-inflammatory biologics market size was valued at USD 93.13 billion in 2022, and the market is now projected to grow from USD 93.32 billion in 2023 to USD 139.80 billion by 2030, exhibiting a CAGR of 5.9% during the forecast period of 2023-2030.
Government has put restrictions on social gatherings, events and moving out from home which make the people homesick. Furthermore, the import and export limitations that excluded certain essential commodities seriously hindered the supply-demand balance. Moreover, the pandemic's impact on telemedicine adoption has spread to other aspects of healthcare delivery. This change has improved patient access to treatments, which has benefited this market. Government has put restrictions on social gatherings, events and moving out from home which make the people homesick. Numerous companies are encountering hurdles due to covid pandemic as the outbreak situation has curtailed production and supply chain which has hindered the market switched to treating covid patients as priority over the other procedures which led the anti-inflammatory biologics market growth. Additionally, manpower shortages affected manufacturing plants and slowed production due to movement restrictions and lockdowns in several regions. Stopped providing on-site maintenance and installations market growth sputtered amid the pandemic.
It is projected that the market would flourish due to the reimbursement for biological therapies and vast applications of biologics in the treatment of inflammatory disorders. Prominent players in the pharmaceutical sector are actively supporting research aimed at developing biologics. Moreover, medical sector advancements are gaining consumers attention towards itself which will propel market growth during forecast period. More potential drug candidates are now taking part in clinical studies as a result. The expected release of these potential pipeline candidates is expected to drive anti-inflammatory biologics market growth considerably. The introduction of monoclonal antibodies and technological advancements has led to produce novel biological therapies with anti-inflammatory effects.
Advancement in the type of tumor necrosis factor used to treat inflammatory diseases from Anti- to Non-Anti-Tumor Necrosis Factor will promote market growth during projected period. Anti-inflammatory biologics is well known for its innovative medical advancements for the development of novel medications to trat various problems. Instead, non-anti-TNF therapies such interleukin inhibitors and Janus Kinase have been popular. The shift is ascribed to the different advantages linked to Non-Anti-Tumor Necrosis Factor. These are some of the major trends which ultimately promote the expansion of market during forecast period.
Comprehensive Analysis of Anti-Inflammatory Biologics Market
The anti-inflammatory biologics market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by Drug Class type, by Application, by Route of Administration and by Distribution Channel. The Drug Class segmentations include Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, and Others, By Application segmentations include Rheumatoid Arthritis, Psoriasis, and Others, By Route of Administration segmentations include Oral and Injection (Subcutaneous and Intravenous), By Distribution Channel segmentations include Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.
The North America region lead the anti-inflammatory biologics market by benefitting a market size of USD 59.37 billion in 2022 due to rising consumers attention towards anti-TNF medications and reimbursement for biological therapies and vast applications of biologics in the treatment of inflammatory disorders.
The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, AbbVie Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), UCB S.A. (Belgium), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Biogen (U.S.) these market players provide a level-playing competitive landscape.
In March 2022, AbbVie, a well-known market player in the medical sector as introduced that RINVOQ (upadacitinib) has been approved by the FDA to treat adult patients with ulcerative colitis which will promote market growth in future.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2030
Base Year 2022
Estimated Year 2023
Forecast Period 2023-2030
Historical Period 2019-2021
Growth Rate CAGR of 5.9% from 2023-2030
Unit Value (USD billion)
Segmentation
By Drug Class
Anti-Tumor Necrosis Factor (TNF)
Interleukins Antagonists
Janus Kinase (JAK) Inhibitors
Others
By Application
Rheumatoid Arthritis
Psoriasis
Others
By Route of Administration
Oral
Injection
Intravenous
Subcutaneous
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country)
U.S.
Canada
Europe (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region)
U.K.
Germany
France
Spain
Italy
Scandinavia
Rest of Europe
Asia Pacific (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region)
Japan
China
India
Australia
Southeast Asia
Rest of Asia Pacific
Latin America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region)
Brazil
Mexico
Rest of Latin America
Middle East & Africa (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region)
GCC
South Africa
Rest of Middle East & Africa
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Rheumatoid Arthritis & Psoriasis – For Key Countries
- 4.2. Pipeline Analysis
- 4.3. Patent Snapshot
- 4.4. New Product Launches
- 4.5. Key Industry Developments - Mergers, Acquisitions and Partnerships
- 5. Global Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030
- 5.1. Market Analysis, Insights and Forecast – By Drug Class
- 5.1.1. Anti-Tumor Necrosis Factor (TNF)
- 5.1.2. Interleukin Antagonists
- 5.1.3. Janus Kinase (JAK) Inhibitors
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast – By Application
- 5.2.1. Rheumatoid Arthritis
- 5.2.2. Psoriasis
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast – By Route of Administration
- 5.3.1. Oral
- 5.3.2. Injection
- 5.3.2.1. Subcutaneous
- 5.3.2.2. Intravenous
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy
- 5.4.3. Online Pharmacy
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030
- 6.1. Market Analysis, Insights and Forecast – By Drug Class
- 6.1.1. Anti-Tumor Necrosis Factor (TNF)
- 6.1.2. Interleukin Antagonists
- 6.1.3. Janus Kinase (JAK) Inhibitors
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast – By Application
- 6.2.1. Rheumatoid Arthritis
- 6.2.2. Psoriasis
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast – By Route of Administration
- 6.3.1. Oral
- 6.3.2. Injection
- 6.3.2.1. Subcutaneous
- 6.3.2.2. Intravenous
- 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy
- 6.4.3. Online Pharmacy
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030
- 7.1. Market Analysis, Insights and Forecast – By Drug Class
- 7.1.1. Anti-Tumor Necrosis Factor (TNF)
- 7.1.2. Interleukin Antagonists
- 7.1.3. Janus Kinase (JAK) Inhibitors
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast – By Application
- 7.2.1. Rheumatoid Arthritis
- 7.2.2. Psoriasis
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast – By Route of Administration
- 7.3.1. Oral
- 7.3.2. Injection
- 7.3.2.1. Subcutaneous
- 7.3.2.2. Intravenous
- 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.4.3. Online Pharmacy
- 7.5. Market Analysis, Insights and Forecast – By Countries/ Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia Pacific Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030
- 8.1. Market Analysis, Insights and Forecast – By Drug Class
- 8.1.1. Anti-Tumor Necrosis Factor (TNF)
- 8.1.2. Interleukin Antagonists
- 8.1.3. Janus Kinase (JAK) Inhibitors
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast – By Application
- 8.2.1. Rheumatoid Arthritis
- 8.2.2. Psoriasis
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast – By Route of Administration
- 8.3.1. Oral
- 8.3.2. Injection
- 8.3.2.1. Subcutaneous
- 8.3.2.2. Intravenous
- 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy
- 8.4.3. Online Pharmacy
- 8.5. Market Analysis, Insights and Forecast – By Countries/ Sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Latin America Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030
- 9.1. Market Analysis, Insights and Forecast – By Drug Class
- 9.1.1. Anti-Tumor Necrosis Factor (TNF)
- 9.1.2. Interleukin Antagonists
- 9.1.3. Janus Kinase (JAK) Inhibitors
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast – By Application
- 9.2.1. Rheumatoid Arthritis
- 9.2.2. Psoriasis
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast – By Route of Administration
- 9.3.1. Oral
- 9.3.2. Injection
- 9.3.2.1. Subcutaneous
- 9.3.2.2. Intravenous
- 9.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.4.3. Online Pharmacy
- 9.5. Market Analysis, Insights and Forecast – By Countries/ Sub regions
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 10. Middle East & Africa Anti-inflammatory Biologics Market Analysis, Insights and Forecast, 2022-2030
- 10.1. Market Analysis, Insights and Forecast – By Drug Class
- 10.1.1. Anti-Tumor Necrosis Factor (TNF)
- 10.1.2. Interleukin Antagonists
- 10.1.3. Janus Kinase (JAK) Inhibitors
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast – By Application
- 10.2.1. Rheumatoid Arthritis
- 10.2.2. Psoriasis
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast – By Route of Administration
- 10.3.1. Oral
- 10.3.2. Injection
- 10.3.2.1. Subcutaneous
- 10.3.2.2. Intravenous
- 10.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.4.1. Hospital Pharmacy
- 10.4.2. Retail Pharmacy
- 10.4.3. Online Pharmacy
- 10.5. Market Analysis, Insights and Forecast – By Countries/ Sub region
- 10.5.1. South Africa
- 10.5.2. GCC
- 10.5.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2022)
- 11.2. Company Profiles
- 11.2.1. AbbVie Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT analysis
- 11.2.1.4. Recent developments
- 11.2.1.5. strategies
- 11.2.1.6. financials (based on availability)
- 11.2.2. Johnson & Johnson Services, Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT analysis
- 11.2.2.4. Recent developments
- 11.2.2.5. strategies
- 11.2.2.6. financials (based on availability)
- 11.2.3. Bristol-Myers Squibb Company
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT analysis
- 11.2.3.4. Recent developments
- 11.2.3.5. strategies
- 11.2.3.6. financials (based on availability)
- 11.2.4. Merck & Co., Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT analysis
- 11.2.4.4. Recent developments
- 11.2.4.5. strategies
- 11.2.4.6. financials (based on availability)
- 11.2.5. Pfizer Inc.
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT analysis
- 11.2.5.4. Recent developments
- 11.2.5.5. strategies
- 11.2.5.6. financials (based on availability)
- 11.2.6. Novartis AG
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT analysis
- 11.2.6.4. Recent developments
- 11.2.6.5. strategies
- 11.2.6.6. financials (based on availability)
- 11.2.7. UCB S.A.
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT analysis
- 11.2.7.4. Recent developments
- 11.2.7.5. strategies
- 11.2.7.6. financials (based on availability)
- 11.2.8. Eli Lilly and Company
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT analysis
- 11.2.8.4. Recent developments
- 11.2.8.5. strategies
- 11.2.8.6. financials (based on availability)
- 11.2.9. Amgen Inc.
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT analysis
- 11.2.9.4. Recent developments
- 11.2.9.5. strategies
- 11.2.9.6. financials (based on availability)
- 11.2.10. Biogen
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT analysis
- 11.2.10.4. Recent developments
- 11.2.10.5. strategies
- 11.2.10.6. financials (based on availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook